Inhibrx Biosciences
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -537 | -564 | -582 |
EBITDA | -29,395 | -29,085 | -31,492 |
EBIT | -29,932 | -29,649 | -32,075 |
Net Income | -33,441 | -32,834 | -35,256 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -38,026 | -30,122 | -33,834 |
Cash | 161,657 | 124,220 | 153,088 |
Basic Shares | 15,585 | 15,487 | 15,478 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $1,300 | $200 | $1,800 | $2,192 |
Gross Profit | -1,183 | -2,085 | 609 | -107,994 |
EBITDA | -125,374 | 1,703,350 | -206,693 | -125,817 |
EBIT | -127,857 | 1,701,065 | -207,884 | -127,042 |
Net Income | -140,055 | 1,687,572 | -241,361 | -145,226 |
Net Change In Cash | 1,300 | 200 | 1,800 | 2,192 |
Free Cash Flow | -129,825 | -197,006 | -197,902 | -115,987 |
Cash | 124,220 | 152,596 | 277,924 | 273,865 |
Basic Shares | 15,487 | 14,475 | 47,130 | 40,108 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$2.34 |
2026-03-31 | -$2.15 |
2025-12-31 | -$2.11 |
2025-09-30 | -$2.28 |